Details

Autor(en) / Beteiligte

• Heeney, Matthew M
• Hoppe, Carolyn C
• Abboud, Miguel R
• Inusa, Baba
• Kanter, Julie
• Ogutu, Bernhards
• Brown, Patricia B
• Heath, Lori E
• Jakubowski, Joseph A
• Zhou, Chunmei
• Zamoryakhin, Dmitry
• Agbenyega, Tsiri
• Colombatti, Raffaella
• Hassab, Hoda M
• Nduba, Videlis N
• Oyieko, Janet N
• Robitaille, Nancy
• Segbefia, Catherine I
• Rees, David C

Titel

A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events

Ist Teil von

• The New England journal of medicine, 2016-02, Vol.374 (7), p.625-635

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In an effort to reduce the rate of sickle cell crises and acute chest syndrome, a trial compared prasugrel with placebo in patients 2 through 17 years of age who had sickle cell anemia. Prasugrel did not have a significant effect on the rate of vaso-occlusive crises. Sickle cell anemia, which is estimated to affect 100 million persons worldwide, is an inherited blood disorder characterized by hemolytic anemia and recurrent vaso-occlusive crises that are associated with hospitalizations, impaired quality of life, and early death. 1 – 3 The pathophysiological mechanism of vaso-occlusion in sickle cell anemia is complex. The polymerization of sickle hemoglobin initiates a cascade of thrombotic and inflammatory insults that result in progressive vascular damage and ischemic end-organ injury. 4 Hydroxyurea is partially effective in reducing the frequency of acute vaso-occlusive events, but it has not been shown to prevent organ damage. 5 There is an unmet need for . . .